Bio-Rad Laboratories
BIO | NYSE
$360.26
-$6.10 (-1.67%)
At close: Nov 16, 2026, 4:00 PM ET
$360.26
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 4:05 PM ET
Bio-Rad Laboratories Company Profile
Company profile explainedCompany Profile
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Key Executives
| Name | Position |
|---|---|
| Norman D. Schwartz | Chairman & Chief Executive Officer |
| Jonathan DiVincenzo | President & Chief Operating Officer |
| Roop K. Lakkaraju | Executive Vice President & Chief Financial Officer |
| Courtney C. Enloe | Executive Vice President, General Counsel & Secretary |
| James J. Barry | Executive Vice President & President of Life Science Group |
| Matthew Werner | Senior Vice President and Chief Compliance & Privacy Officer |
| Michael Crowley | Executive Vice President of Global Commercial Operations |
| Nanditha R. Yelamanchi | Executive Vice President of Global Human Resources |
| Rajat Mehta | Executive Vice President of Global Commercial Operations |
| Ruben Argueta | Vice President of Investor Relations |
Bio-Rad Laboratories
| Country | United States |
| IPO Date | Feb 27, 1980 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 7,450 |
| CEO | Norman D. Schwartz |
Contact Details
1000 Alfred Nobel Drive Hercules,
California 94547 United States
Stock Details
| Ticker Symbol | BIO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000012208 |
| CUSIP Number | 090572207 |
| ISIN Number | US0905722072 |
| SIC Code | 3826 |
Recent News
- 3 days ago / globenewswire.comBIO-key Q3 Software License Fees Grew 39%, Its Third Consecutive Quarter of Double-Digit Growth, Driven Primarily by Momentum in the Middle East and Europe; Hosts Call Today at 10am ET
- 4 days ago / globenewswire.comBIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
- 5 days ago / globenewswire.comBIO-key Enters Gaming / Hospitality Market with Contract from Major U.S. Casino Resort
- 6 days ago / seekingalpha.comBio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript
- 6 days ago / globenewswire.comDyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
- 8 days ago / zacks.comWhy Bio-Rad (BIO) International Revenue Trends Deserve Your Attention
- 12 days ago / globenewswire.comMedicus Pharma to Present at BIO-Europe 2026
- 12 days ago / marketbeat.comWhat Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call
- 12 days ago / seekingalpha.comBio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comBio-Rad Laboratories (BIO) Q3 Earnings Top Estimates
Add to Watchlist
Select watchlists to add or remove BIO